(Q34305866)

1 August 2017

1 reference

title

Metabolic complications associated with antiretroviral therapy (English)

1 reference

1 August 2017

anti-retroviral agent

0 references

author name string

Jain RG

1

1 reference

1 August 2017

Furfine ES

2

1 reference

1 August 2017

Pedneault L

3

1 reference

1 August 2017

White AJ

4

1 reference

1 August 2017

Lenhard JM

5

1 reference

1 August 2017

language of work or name

1 reference

1 September 2001

1 reference

1 August 2017

1 reference

1 August 2017

51

1 reference

1 August 2017

3

1 reference

1 August 2017

151-177

1 reference

Lipodystrophy associated with nevirapine-containing antiretroviral therapies.

1 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

Decreased bone formative and enhanced resorptive markers in human immunodeficiency virus infection: indication of normalization of the bone-remodeling process during highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

The adipsin-acylation stimulating protein system and regulation of intracellular triglyceride synthesis

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

HIV wasting syndrome: treatment update

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

Chemotherapeutic agents for human immunodeficiency virus infection: mechanism of action, pharmacokinetics, metabolism, and adverse reactions

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

Influence of protease inhibitor therapy on lipoprotein metabolism.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

Hyperlactatemia and antiretroviral therapy: the Swiss HIV Cohort Study

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

Genetics of human obesity: recent results from linkage studies

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

Lipodystrophy defined by a clinical score in HIV-infected men on highly active antiretroviral therapy: correlation between dyslipidaemia and steroid hormone alterations

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

Correlation between increased cortisol:DHEA ratio and malnutrition in HIV-positive men.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

Mitochondrial DNA polymerase gamma is expressed and translated in the absence of mitochondrial DNA maintenance and replication

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

AZT treatment induces molecular and ultrastructural oxidative damage to muscle mitochondria. Prevention by antioxidant vitamins

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

Subcutaneous adipocyte apoptosis in HIV-1 protease inhibitor-associated lipodystrophy

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

Suppression of preadipocyte differentiation and promotion of adipocyte death by HIV protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

Protease inhibitor-associated hyperglycaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

Fat distribution in HIV-infected patients reporting truncal enlargement quantified by whole-body magnetic resonance imaging

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

[Benign symmetrical lipomatosis ("peripheral lipodystrophy") during antiretroviral therapy of HIV infection]

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

Protease inhibitors and adipocyte differentiation in cell culture.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

Soluble receptors for tumor necrosis factor are markers for clinical course but not for major metabolic changes in human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

The role of the cytokines, interferon alpha and tumor necrosis factor in the hypertriglyceridemia and wasting of AIDs

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

Circulating interferon-alpha levels and hypertriglyceridemia in the acquired immunodeficiency syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

Metformin in the treatment of HIV lipodystrophy syndrome: A randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

Fasting hyperinsulinemia in human immunodeficiency virus-infected men: relationship to body composition, gonadal function, and protease inhibitor use.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

Fasting hyperinsulinemia and changes in regional body composition in human immunodeficiency virus-infected women

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

Benign symmetric lipomatosis associated with protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

Alterations in bone turnover in HIV-positive patients

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

Gemfibrozil effectively lowers protease inhibitor-associated hypertriglyceridemia in HIV-1-positive patients

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

Disorders of the complement system in lipodystrophy

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

Nucleoside reverse transcriptase inhibitor-induced mitochondrial toxicity as an etiology for lipodystrophy

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

HIV protease inhibitors: advances in therapy and adverse reactions, including metabolic complications

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

Discovery of ritonavir, a potent inhibitor of HIV protease with high oral bioavailability and clinical efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

Reduction of buffalo hump by switching to amprenavir in an HIV-infected patient

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

Oral isotretinoin therapy in severe acne induces transient suppression of biochemical markers of bone turnover and calcium homeostasis

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

Preliminary evidence that DEXA provides an accurate assessment of body composition.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

Serum lipid levels associated with increased risk for cardiovascular disease is associated with highly active antiretroviral therapy (HAART) in HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

IBC's 6th International Symposium on Obesity and 3rd International Symposium on Insulin Resistance: March 22-25, 1999, Washington, DC.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

Dietary fat alters HIV protease inhibitor-induced metabolic changes in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

HIV protease inhibitors block adipogenesis and increase lipolysis in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

Effects of troglitazone and metformin on glucose and lipid metabolism: alterations of two distinct molecular pathways

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

The RXR agonist LG100268 causes hepatomegaly, improves glycaemic control and decreases cardiovascular risk and cachexia in diabetic mice suffering from pancreatic beta-cell dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

Stimulation of vitamin A(1) acid signaling by the HIV protease inhibitor indinavir

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

Partial lipodystrophy, mesangiocapillary glomerulonephritis, and complement dysregulation. An autoimmune phenomenon

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

Chicoric acid analogues as HIV-1 integrase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

Body shape changes in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

"Buffalo hump" in men with HIV-1 infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

Effects of antiviral nucleoside analogs on human DNA polymerases and mitochondrial DNA synthesis

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

Hyperosmolar nonketotic diabetic syndrome following treatment of human immunodeficiency virus infection with didanosine

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

Reversal of protease inhibitor-related visceral abdominal fat accumulation with recombinant human growth hormone

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

A retrospective study to determine if hydroxyurea augmentation of antiretroviral drug regimens that contain ddI and/or d4T increases the risk of developing peripheral neuropathy in HIV-1 infected individuals

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

Metabolic aspects of HIV: associated wasting

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

Excessive Dietary Intake of Vitamin A Is Associated with Reduced Bone Mineral Density and Increased Risk for Hip Fracture

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

Intervention for hyperlipidemia associated with protease inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

Abacavir and diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

Incidence of neuropathy in HIV-infected patients on monotherapy versus those on combination therapy with didanosine, stavudine and hydroxyurea

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

HIV nucleoside analogues: new adverse effects on mitochondria?

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

The mechanism of insulin resistance caused by HIV protease inhibitor therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

Ritonavir increases the level of active ADD-1/SREBP-1 protein during adipogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

Stable or increasing bone mineral density in HIV-infected patients treated with nelfinavir or indinavir

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

Drug interaction of isotretinoin and protease inhibitors: support for the cellular retinoic acid-binding protein-1 theory of lipodystrophy?

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

Nelfinavir mesylate: a protease inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

Bone mineral density in patients with human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

Thiazolidinediones inhibit alkaline phosphatase activity while increasing expression of uncoupling protein, deiodinase, and increasing mitochondrial mass in C3H10T1/2 cells

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

Detection and quantification of the control proteins of the alternative pathway of complement in 3T3-L1 adipocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

Prolonged therapy with the fusion inhibitor T-20 in combination with oral antiretroviral agents in an HIV-infected individual

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

Diabetes mellitus associated with protease inhibitor use

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

A pilot study of exercise training to reduce trunk fat in adults with HIV-associated fat redistribution

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

Fat distribution and metabolic changes in patients with HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

The effects of discontinuing stavudine therapy on clinical and metabolic abnormalities in patients suffering from lipodystrophy

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

Morphologic criteria and detection of apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

Sagittal diameter in comparison with single slice CT as a predictor of total visceral adipose tissue volume

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

Body weight changes with protease inhibitor treatment in undernourished HIV-infected patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

Hyperlipidemia under treatment with proteinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

Bone remodelling in human immunodeficiency virus-1-infected patients. A histomorphometric study

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

Hypocholesterolemia is associated with immune dysfunction in early human immunodeficiency virus-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

The effect of protease inhibitors on weight and body composition in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

The Complement Abnormalities of Lipodystrophy

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

Retinoid-induced epiphyseal plate closure in guinea pigs

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

Marked hypertriglyceridaemia associated with ritonavir therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

Changes in calciotropic hormones and biochemical markers of bone metabolism in patients with human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

Use of fenofibrate in the management of protease inhibitor-associated lipid abnormalities

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

Monitoring changes in fat-free mass in HIV-positive men with hypotestosteronemia and AIDS wasting syndrome treated with gonadal hormone replacement therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

Effects of troglitazone on insulin sensitivity in HIV-infected patients with protease inhibitor-associated diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

Body-fat measurement in patients with acquired immunodeficiency syndrome: which method should be used?

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

Recombinant human growth hormone improves the fat redistribution syndrome (lipodystrophy) in patients with HIV.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

Agreement of skinfold measurement and bioelectrical impedance analysis (BIA) methods with dual energy X-ray absorptiometry (DEXA) in estimating total body fat in Anglo-Celtic Australians

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

Bone mineral loss in HIV-positive patients receiving antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

HIV protease inhibitors block human preadipocyte differentiation, but not via the PPARgamma/RXR heterodimer

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

Deoxyribonucleotide analogs as inhibitors and substrates of DNA polymerases

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

Insulin resistance in HIV protease inhibitor-associated diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900148-6

7 January 2021

10.1016/S0166-3542(01)00148-6

Identifiers

DOI

1 reference

1 August 2017

1 reference